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Abstract: The light sensing outer segments of photoreceptors (PRs) are renewed every ten days due to
their high photoactivity, especially of the cones during daytime vision. This demands a tremendous
amount of energy, as well as a high turnover of their main biosynthetic compounds, membranes, and
proteins. Therefore, a refined proteostasis network (PN), regulating the protein balance, is crucial for
PR viability. In many inherited retinal diseases (IRDs) this balance is disrupted leading to protein
accumulation in the inner segment and eventually the death of PRs. Various studies have been
focusing on therapeutically targeting the different branches of the PR PN to restore the protein balance
and ultimately to treat inherited blindness. This review first describes the different branches of the
PN in detail. Subsequently, insights are provided on how therapeutic compounds directed against the
different PN branches might slow down or even arrest the appalling, progressive blinding conditions.
These insights are supported by findings of PN modulators in other research disciplines.
Keywords: protein trafficking; protein folding; protein degradation; chaperones; chaperonins; heat
shock response; unfolded protein response; autophagy; therapy
1. Introduction
The rod and cone photoreceptor (PR) cells are the most abundant cell types in the human retina,
with ~6.4 million cones and up to 125 million rods per adult retina [1]. PRs are highly specialized,
polarized neurons of neuroepithelial origin, consisting of morphologically and functionally distinct
cellular compartments, including a synaptic terminal, an inner segment (IS), an outer segment (OS),
and a connecting cilium bridging the IS and OS. The classical division into rods and cones is based
on their different OS morphology and differential expression of subtypes of opsin. The rod outer
segments are long, thin, rod-shaped organelles containing rhodopsin in large stacks of membranous
discs, allowing to process variations in dim-light conditions, but they lose this ability in bright light
conditions. The OSs of cones represent a shorter conical organelle containing either S-opsin, M-opsin,
or L-opsin, which are less sensitive compared to rhodopsin, but are perfectly suited to process bright
light of different wavelengths, allowing color vision [2].
Despite the difference in photosensitivity, the process of converting light stimuli into biochemical
signals, the phototransduction cascade, is almost indistinguishable between rods and cones [3,4].
In rods, upon capture of a photon, the chromophore 11-cis retinal, which is conjugated to a rhodopsin
molecule, undergoes a conformational change that isomerizes it to all-trans retinal leading to the
activation of rod opsin. The activated opsin molecule is now able to bind and subsequently activate the
G-protein, transducin. Transducin consists of three subunits: Gα, Gβ, and Gγ. In its inactive state, Gα
is bound to a GDP. When transducin gets activated by rhodopsin, this GDP is replaced by a GTP and
subsequently Gα dissociates from the Gβγ subunit. The GTP bound Gα is now able to displace one
of the two inhibitory γ-subunits of cGMP-specific 3′,5′-cyclic phosphodiesterase (PDE6) causing the
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exposure of one of the two catalytic sites of the PDE6αβ heterodimer (PDE6α’ for cones). The exposed
catalytic sites are now able to hydrolyze multiple cGMP molecules to 5′-GMP. In the dark state, cGMP
binds to its specific cation channel allowing a steady movement of cations into the OS, which is
compensated by the eﬄux of cations from the OS by Na+/Ca2+, K+ exchangers (NCKXs) [5]. Due to the
hydrolysis of cGMP, its levels decrease causing the closure of cation channels in the OS. The resulting
hyperpolarization of the OS membrane spreads throughout the cell, eventually reaching the synaptic
terminal. Here, the hyperpolarization causes closure of calcium channels and subsequently a decrease
in calcium-dependent synaptic glutamate release [3,4], which activates the glutamate receptors of the
bipolar cells postsynaptically, transducing the brain-bound electrical signal [6].
The phototransduction cascade, carried out in only a few milliseconds, is based on capture
of one single photon in dim light. However, in bright daylight conditions, immense amounts of
photons are caught by the human PRs, mainly cones, every second, which causes toxic photo-oxidative
damage to the OS components. These components, which include most proteins involved in the
phototransduction cascade, are therefore continuously renewed (~10% every day for human PRs), by
incorporating newly synthesized PR discs at the OS base, and shedding the oldest membrane discs at
the cell’s tip [7,8]. The shed OS tips are subsequently phagocytosed by the retinal pigment epithelium
(RPE) cells, which is the highest active phagocytic process in our body [9,10]. Because of this highly
active protein turnover, a mutation in a gene encoding a protein involved in this machinery most often
leads to PR cell death, a classical hallmark of many inherited retinal diseases (IRDs).
IRDs are a genetically heterogeneous group of rare eye disorders with a progressive manifestation
causing vision loss or even complete blindness [11]. Mutations in many genes that are required for
PR function were found to be causative for IRDs. These include genes encoding proteins involved in
protein trafficking, splicing, energy metabolism, and photoreceptor structure [12]. The compartments
of PRs most prominently implicated in IRDs are the OS and the connecting cilium. The connecting
cilium correlates with the transition zone of a primary cilium and functions as a gatekeeper to regulate
the molecular composition of the OS. Thus, the OS, connecting cilium, and the immediately adjacent
basal body, form the photoreceptor sensory cilium, one of the most highly specialized primary cilia,
fully optimized for photoreception and transduction [13,14]. Hence, IRDs with defects in these
compartments are referred to as retinal ciliopathies [11].
Defects in the conserved ciliary processes mostly manifest as syndromic ciliopathy conditions,
affecting multiple organs. The most prominent ciliopathies in which the retina is affected
are Bardet–Biedl syndrome (BBS), Joubert syndrome (JS), Meckel–Gruber syndrome (MKS), and
Senior–Løken syndrome (SLS) [4,11]. Because PRs are highly specialized, polarized neurons, retinal
ciliopathies often also occur in a nonsyndromic fashion, affecting ciliary proteins specific to rods
and/or cones. Based on the PR cell type affected, different IRDs can be categorized, including retinitis
pigmentosa (RP), Leber congenital amaurosis (LCA), cone-rod dystrophy (CRD), and achromatopsia
(ACHM) [4,11].
RP is the most common form of inherited blindness worldwide, with a prevalence of about 1:4000
people. The cells that are affected initially in RP are the rods leading to night blindness and loss of
peripheral vision. Secondary, cones are most often also affected as the disease progresses [15].
LCA is the most severe form of inherited retinal degeneration, causing patients to suffer from
severe visual impairment to complete blindness before the first year of life. With LCA, both rods and
cones are affected at early stages often leading to complete blindness [16].
Another early onset form of hereditary retinal dystrophy is CRD, which manifest in the opposite
order compared to RP, since in CRD cones are initially affected, followed by the loss of rods [17].
A disease in which specifically the cones deteriorate is ACHM, most often leading to complete
color blindness [18].
Apart from some specific exceptions, most of the above described blinding conditions are still
considered incurable. However, significant and promising progress has been made with therapeutic
studies targeting specific genes and/or mutations, most prominently by employing gene augmentation
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and antisense-oligo nucleotide (AON)-based techniques [19,20]. Yet, a major disadvantage of these
treatments is that they are complex and invasive for the patient. On top of that, for nearly every
mutation, a personalized approach needs to be developed. Therefore, there is a high interest in
pharmacological agents with a broad range of disease targets. To discover such agents, a growing
number of studies have focused on a common phenomenon seen in many IRDs before the actual
death of rods and cones: the accumulation and/or misfolding of proteins in the inner segment of the
photoreceptors [21].
This phenomenon can be explained by the malfunction of several processes, all involved in protein
homeostasis or proteostasis. A first process is the disruption of protein transport from the IS to the OS
(Figure 1A). As the OS lacks the biosynthesis machinery for proteins and lipids, all of the components
required for OS morphogenesis, maintenance, and sensory functions must be transported from the
endoplasmic reticulum (ER), located in the IS, to the OS [2], across the connective connecting cilium stalk.
Therefore, defects in this transport most often lead to the accumulation of proteins in the IS. Another
process involved in the accumulation of proteins in the IS is the dysregulation of pathways involved in
protein degradation, including ER-associated degradation (ERAD) and autophagy (Figure 1C). Finally,
also incorrect folding of specific proteins due to loss-of-function mutations can results in protein
accumulation in the IS (Figure 1B). An accumulation of misfolded proteins in the ER membrane or
in the cytoplasm of the PRs can induce the heat shock response (HSR) and/or the unfolded protein
response (UPR). Continuous activation of these responses will ultimately lead to death of PRs [21].
In this review the above mentioned branches of the proteostasis network will be described in detail.
Subsequently, we will explain how potential therapeutic agents directed against these branches might
slow down or even arrest the dramatic blinding conditions, supported by findings of PN modulators
in other research disciplines.
2. The Different Branches of the Proteostasis Network
2.1. Pathways Involved in Protein Trafficking
2.1.1. Chaperones Involved in Lipid-Dependent Trafficking
Many PR-specific proteins depend on post-translational lipid modifications, including prenylation
and myristoylation, for correct localization to the OS and their anchoring at one of the OS membranes [22].
Protein prenylation involves the transfer of either a farnesyl or a geranylgeranyl moiety to the C-terminal
cysteine(s) of the target protein by farnesyltransferase (FTase) and geranylgeranyltransferase (GGTase-I),
respectively [23]. Several chaperones are involved in this prenylation process, including AIPL1, PDE6D,
and UNC119.
Aryl hydrocarbon receptor (AhR)-interacting protein-like 1 (AIPL1) was first discovered in
association with Leber congenital amaurosis (LCA) [24]. Mutations in the AIPL1 gene encoding
for AIPL1 results in LCA4, one of the most severe forms of LCA leading to blindness in early
childhood [25]. Since then, studies were set up to unravel the function of the AIPL1 protein. Studies
in AIPL1 knockdown and knockout mouse models revealed that AIPL1 functions as a chaperone for
PDE6 [26,27]. In these mouse models protein levels and activity of PDE6 were severely reduced, whereas
other photoreceptor proteins were unaffected. Other studies suggest that AIPL1 is also necessary
for the maintenance of PRs by enhancing the essential farnesylation reaction [28,29]. Several retinal
proteins, including PDE, transducin, and rhodopsin kinase (GRK1) are known to be farnesylated [30].
These findings are in line with the observed rapid degeneration of rods and cones in the animal models,
as well as in LCA4 patients.
Another chaperone, mainly involved in the trafficking of prenylated proteins, is PDE6D [8,31].
In mice, knockout of PDE6D results in mislocalization of prenylated PR proteins, including PDE6, GRK1,
and Gγ [32]. In human, mutations in PDE6D are associated with Joubert syndrome (JS) [33,34]. This
syndromic condition can be explained by mislocalization of other critical cargos of PDE6D important
for the development and stability of the primary cilium. These cargos include inositol polyphosphate
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5-phosphatase E (INPP5E) and retinitis pigmentosa GTPase regulator (RPGR) [33,35]. The trafficking
of these cargos comprises of several steps [36,37]. First, PDE6D solubilizes the prenylated protein from
the ER by sequestering the hydrophobic farnesyl or geranylgeranyl tail. Subsequently, PDE6D targets
the cargo to the destination membrane by association with a peripherally membrane bound docking
protein. Finally, binding of the displacement factor ARL3 to PDE6D causes a reduction in size of the
hydrophobic cavity resulting in the release of the cargo [38]. PDE6D can now travel back to repeat
its cycle.
UNC119 shares significant sequence and structural homology with the prenyl-binding protein
PDE6D [37]. Similar to PDE6D, UNC119 is also a subject of ARL3-dependent cargo release, and therefore
the transport mechanism of PDE6D and UNC119 are highly identical. However, a remarkable difference
between PDE6D and UNC119 is the ARL3-dependent release of their cargo. In contrast to PDE6D, the
hydrophobic pocket of UNC119 is expanded upon binding of ARL3, thereby weakening the interaction
with the cargo instead of squeezing the lipid out of the hydrophobic pocket [39]. This might be partly
explained by the binding of different lipid moieties of both chaperones. Whereas PDE6D sequesters
prenylated proteins, UNC119 is known to bind myristoylated cargo [31,40]. UNC119 has been shown to
be important in the trafficking of transducin, which is myristoylated on its α-subunit [41]. In UNC119
knockout mice, the trafficking of transducin to the OS during dark adaptation was significantly
impaired, contributing to the observed slow retinal degeneration [42]. The observed mislocalization
of transducin in these mice is not complete, supporting the fact that transducin is trafficked by other
proteins, including PDE6D. Interestingly, a study performed in Pde6d;Unc119 double-knockout mice
showed partially improved rhodopsin kinase (GRK1) expression and trafficking in cones compared to
Pde6d single-knockout mice [43]. Based on these findings, the authors suggest that the transport by
PDE6D and UNC119 in cones might be interdependent. The improvement found in only cones is in
line with the relatively mild phenotype seen in patients with a truncating mutation in UNC119, which
is associated with late onset CRD [44].
2.2. Pathways Involved in Protein Folding
2.2.1. Chaperonins, Phosducins and Ric8A
In addition to the classic and ubiquitous molecular chaperones from the heat shock protein
superfamily (discussed below), various studies have focused on chaperones and co-chaperones
involved in folding and assembly of PR-specific proteins.
One of the PR-specific proteins that needs targeted guidance for its correct folding and assembly
is transducin. The folding and assembly of the full transducin protein complex is performed in two
distinct steps. In the first step, the so-called chaperonins or CCTs (chaperonins containing TCP-1) are
involved. CCTs are protein-folding ATPase complexes consisting of two stacked rings, which form
a central cavity [45]. The β-subunit of transducin (Gβ) is able to enter this cavity. Once transducin
enters, ATP binding occurs, resulting in the closure of the cavity by hydrolysis of the just bound ATP
molecule [46]. In addition to ATP, the folding of Gβ requires a co-chaperone, phosducin-like protein 1
(PhLP1). Binding of PhLP1 induces conformational changes of CCT that lock the β-propeller structure
of Gβ. Subsequently, Gβ rotates inside the cavity followed by its release in complex with PhLP1.
PhLP1 is required for the formation of the Gβγ dimer [47].
The second step involves the trafficking of the Gβγ dimer to the OS by phosducin, another
member of the phosducin family of proteins. Phosducin forms a complex with Gβγ by sequestering
the hydrophobic farnesyl residue of Gγ [48]. The farnesyl residue serves as a membrane anchor, which
targets Gβγ to the OS [49]. Another speculated function of phosducin is the protection of Gβγ against
ubiquitination and degradation by the proteasome [50].
CCTs are also involved in the folding and assembly of the BBSome [51], a protein complex that
regulates the ciliary import, export, and intraciliary trafficking of molecules [52]. Mutations in genes
coding for BBSome proteins most often result in the development of Bardet–Biedl syndrome, one of the
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syndromic ciliopathy conditions in which the retina is affected [53], as indicated in the introduction.
For some of the BBSome proteins it was shown that these proteins contain a β-propeller fold, similar
to Gβ [54]. Whether or not the folding and assembly of the BBSome proteins is comparable to the
situation of Gβ remains to be elucidated.
It remains largely unknown if the α-subunit of transducin also needs assistance in correct folding
and trafficking to the OS before it forms a heterotrimeric complex with Gβγ. However, evidence
is emerging that resistance to inhibitors of cholinesterase 8 (RIC8) proteins function as ubiquitous
chaperones for Gα [55]. The two known isoforms—RIC8A and RIC8B—each regulate specific classes
of Gα [56]. Although the specific PR class of Gα and its relation to RIC8 has not been investigated,
it has been shown that a closely related form interacts with RIC8A [57]. The proposed mode of
action of RIC8A is to positively regulate Gα by acting as a guanine nucleotide exchange factor (GEF).
RIC8A preferentially binds GDP-bound Gα and causes GDP release. Subsequently, RIC8A assists in
organizing a de novo nucleotide-binding pocket for binding of GTP. The RIC8A-Gα complex breaks
apart when a GTP molecule binds. Subsequent hydrolysis of GTP results in the binding of Gα to the
Gβγ yielding the fully assembled heterotrimeric complex [58]. Taken together, CCT together with
PhLP1 regulate the folding of the transducin β-subunit. Subsequently, Gβ forms a dimer with Gγ by
guidance of PhLP1. Finally, the Gβγ dimer is trafficked to the OS by phosducin, where it can bind to
Gα. RIC8A has been proposed as the chaperone of Gα and its assembly to the Gβγ dimer.
2.2.2. Heat Shock Response (HSR)
The HSR is known to be present in every living organism, and functions as an essential survival
mechanism against extracellular challenges, such as increased temperatures, and intracellular stressors
such as oxidative stress, that lead to protein misfolding [21,59]. The HSR is featured by an extremely
rapid activation of gene expression, leading to a remarkable increase in molecular chaperones, including
heat shock proteins (HSPs) [60]. In vertebrates, the HSR is regulated by a family of transcription
factors, which includes six members (HSF1-4, HSFX, and HSFY) [59]. HSF1 is believed to be the master
regulator of molecular chaperone synthesis upon protein misfolding [61]. Under normal physiological
conditions, monomeric HSF1 is repressed and localized in the cytosol by interacting with molecular
chaperones, including HSP90, HSP70, and the chaperonin CCT. When a threshold of misfolded proteins
is reached, the chaperones dissociate from HSF1 leading to trimerization and nuclear accumulation of
HSF1 followed by transcriptional activation of HSPs. The major HSPs involved in the HSR include
HSP90, HSP70, and HSP60 [61].
HSP90 and HSP70 are able to associate with the hydrophobic regions of the protein, and thereby
preventing binding to other hydrophobic moieties [61]. Subsequently, they assist in the folding of these
hydrophobic regions in such a way that the hydrophobic groups are not exposed. Furthermore, they
aid in overcoming the energy thresholds of the intermediate folding states of the protein [62]. Similar
to HSP90 and HSP70, the chaperonin HSP60 is also able to bind hydrophobic residues of proteins.
In contrast, the barrel-shaped HSP60 is more passively involved in the folding of proteins by creating a
favorable microenvironment for the hydrophobic regions in its central cavity [63].
2.2.3. Unfolded Protein Response (UPR)
A more specific cellular stress response related to the ER is the UPR. The UPR is activated in
response to an accumulation of unfolded and/or misfolded proteins in the lumen of the ER [64].
The activation of the UPR aims to reduce ER stress and restore proteostasis in three distinct ways:
an initial response to reduce protein synthesis, a second wave of increased production of molecular
chaperones involved in protein folding to increase folding capacity, and finally the degradation of
misfolded proteins when the folding capacity is insufficient to restore functional protein balance.
It is generally accepted that a member of the HSP70 family, BiP/GRP78, is the key regulator in the
activation of the UPR [65]. BiP has been shown to associate with all three transmembrane sensors of the
UPR, including inositol requiring enzyme-1 (IRE1) α and β, protein kinase RNA (PKR)-like ER kinase
Genes 2019, 10, 557 6 of 25
(PERK), and activating transcription factor 6 (ATF6) α and β. Under normal physiological conditions,
BiP associates with the ER luminal domain of IRE1 and PERK via its ATPase domain, maintaining
them in an inactive monomeric state.
The interaction of BiP with ATF6 masks a binding site to coat protein-II (COP-II) vesicles, thereby
preventing ATF6 translocation to the Golgi. Upon ER stress, BiP dissociates from the sensors and
binds to misfolded proteins. Subsequently, IRE1 and PERK are able to oligomerize followed by their
trans-autophosphorylation and ATF6 traffics to the Golgi for further processing and activation.
Dissociation of BiP from IRE1 results in the activation of its RNase domain. This activation is
sustained by binding of HSP47 to the luminal domain of IRE1, thereby hindering the binding of
BiP [66]. Subsequently, a single mRNA encoding for X-box binding protein 1 (XBP1) is targeted for
non-conventional splicing [67].
These spliced XBP1s trigger the expression of molecular chaperones and components of ERAD in
order to relieve the load on the ER and eventually restore protein balance [68]. One of the upregulated
chaperones is the ER resident co-chaperone ERdj4, which eases and stabilizes the binding of BiP [69].
Furthermore, it has been shown that protein disulfide isomerase A6 (PDIA6) plays an important role in
the conversion of IRE1 to its monomeric state [70]. Based on these findings, it is speculated that ERdj4
and PDIA6 are important regulators of the IRE1 negative feedback loop. Activation of PERK leads to
phosphorylation of the α-subunit of eukaryotic translation initiation factor 2 (eIF2α), thereby hindering
the conversion of eIF2-GDP to eIF2-GTP by the GEF eIF2B [71]. The inactivation of eIF2α leads to
overall decrease in mRNA translation and thus protein synthesis. Although, global mRNA translation
is reduced, some specific mRNAs are favored to be translated, including activation transcription
factor 4 (ATF4) [72]. ATF4 is able to activate the transcription of various genes involved in protein
folding, autophagy, and apoptosis, including CCAAT/enhancer-binding protein (C/EBP) homologous
protein (CHOP), ER oxidoreductin 1 (ERO1), and growth arrest and DNA damage-inducible protein
(GADD34). GADD34 plays a role in the negative feedback loop for PERK by acting as a cofactor
in the dephosphorylation of eIF2α [73]. CHOP and ERO1 mainly play a role in prolonged PERK
activation [74], which will be discussed below.
Under ER stress, ATF6 binds to COP-II vesicles and traffics to the Golgi [75]. Here, it is cleaved by
proteases S1P and S2P resulting in a cytosolic fragment [76]. This fragment travels into the nucleus to
regulate transcription of specific UPR genes, including CHOP and XBP1. Interestingly, XBP1s and ATF6
are able to heterodimerize, and subsequently induce the expression of genes involved in ERAD [77].
2.3. Pathways Involved in Protein Degradation
2.3.1. ER-associated Degradation (ERAD)
Folding and maturation of proteins is a complicated process that is highly susceptible to errors.
Up to 30% of all newly synthesized proteins are affected by such errors and are therefore degraded
by the proteasome before they reach their defective mature state [78]. An important player in
proteasomal-dependent protein degradation is ERAD. The process of ERAD can be divided into three
consecutive steps: recognition of misfolded proteins in the ER, retrotranslocation of these proteins into
the cytosol, and ubiquitin-dependent degradation by the ubiquitin–proteasome system (UPS) [79].
The recognition of misfolded proteins depends on the detection of substructures within
proteins, including exposed hydrophobic regions, unpaired cysteine residues, and immature
glycans [80]. The latter involves the lectin-type chaperones calnexin and calreticulin, which can
bind to glycans possessing the Glc3Man9GlcNAc2 structure produced by deglucosylation [81].
Incompletely or misfolded proteins undergo multiple rounds of reglucosylation by uridine diphosphate
(UDP)-glucose:glycoprotein glucosyltransferase (UGGT) and subsequent folding by reassociation with
calnexin or calreticulin, eventually resulting in the mature protein conformation [82].
On the other hand, terminally misfolded proteins must be extracted from this calnexin/calreticulin
cycle. This extraction is regulated by the removal of terminal mannose residues from core
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glycans by mannosidases, including ER mannosidase I (ERMANI), ER degradation-enhancing
α-mannosidase-like protein 1 (EDEM1), EDEM3, or Golgi-resident mannosidase α class 1C member 1
(MAN1C1) [83–85]. In this way, ERAD can discriminate between terminally misfolded proteins and
their fully functional counterparts.
Since the ubiquitin-dependent degradation by the UPS is performed in the cytosol, terminally
misfolded proteins subjected to ERAD have to be transported through the ER membrane via a
transmembrane channel, called the retrotranslocon [86]. The exact composition of this channel is yet
unknown. However, it has been shown that the membrane protein Derlin-1 and various E3 ubiquitin
ligases are part of the retrotranslocon complex [87]. Once a small part of the substrate for ERAD is
exposed to the surface of the ER, the substrate becomes a subject for poly-ubiquitination. Subsequently,
the p97/valosin-containing protein (VCP), which is a member of the type II AAA+ protein family of
ATPases, together with its cofactors, possessing ubiquitin-binding domains (UBDs), cooperatively
produce a driving force for the retrotranslocation [88].
Retrotranslocated substrates for ERAD often possess exposed hydrophobic domains. Therefore, it
is important that these substrates should be rapidly transported to the UPS for degradation to prevent
aggregation. A chaperone complex consisting of BCL-2-associated athanogene 6 (BAG6), ubiquitin-like
protein 4A (UBL4A), transmembrane domain recognition complex 35 (TRC35), and co-chaperone small
glutamine-rich TPR-containing protein α (SGTA) has been shown to play an important role in the
trafficking of ERAD substrates to the UPS by binding to the hydrophobic domains [89].
2.3.2. Autophagy
Another very important process involved in protein degradation is autophagy. Multiple forms
of autophagy are known, including macroautophagy, chaperone-mediated autophagy (CMA), and
microautophagy [90].
Macroautophagy is the most common form of autophagy and therefore often referred to
simply as autophagy. Autophagy consists of multiple consecutive phases, including initiation,
nucleation, elongation, closure, and fusion to the lysosome. The initiation phase is tightly regulated by
AMP-activated protein kinase (AMPK) and mammalian target of rapamycin complex I (mTORC1) [91].
In addition, factors expressed resulting from ER stress are also able to trigger the initiation phase.
It all starts with the formation of the Unc-51-like kinase 1 (ULK1) complex followed by the
phosphorylation of the class III phosphoinositide 3-kinase (PI3KC3) complex I leading to the nucleation
of the phagophore [91,92]. Subsequently, autophagosome elongation and closure requires two
ubiquitin-like conjugation systems, including an ATG7 dependent system and an ATG5-ATG12
dependent system. Together they are responsible for the lipidation, by phosphatidyethanolamine (PE),
from cleavage of microtubule-associated protein 1 light chain 3 (LC3). Membrane sources in form of
lipids needed for the elongation of the autophagosomal membrane are provided by ATG9-dependent
vesicle trafficking. After closure of the autophagosomal membrane, the autophagosome has to fuse
with the lysosome to form an autolysosome in order to degrade its enclosed cargo [93].
A selective form of autophagy is CMA, which to date is only identified in mammals [94]. This
form of autophagy is specific for proteins containing a KFERQ motif in their amino acid sequence [95].
Heat shock cognate of the HSP70 family, HSC70, is able to recognize this motif and subsequently targets
these proteins to the lysosome [96]. Here, it binds to the lysosomal receptor LAMP-2A and facilitates,
together with its co-chaperones, in the unfolding process of the substrate in order to translocate it into
the lysosome [97].
Microautophagy is a process in which cytoplasmic cargo is directly engulfed into the lysosome [98].
This process is triggered by the same stimuli compared to common autophagy, but in contrast it mainly
facilitates the degradation of smaller substrates, including misfolded proteins. Similar to CMA, Hsc70
is involved in the protein cargo selection for degradation [99].
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Figure 1. Schematic representation of the different branches of the proteostasis network, divided
into trafficking, folding and degradation. (A) Trafficking: Protein prenylation involves the transfer
of either a farnesyl or a geranylgeranyl moiety to the C-terminal cysteine(s) of the target protein
by farnesyltransferase (FTase) and geranylgeranyltransferase (GGTase-I), respectively. Chaperones
involved in regulation of this prenylation process and trafficking of prenylated proteins, include AIPL1,
PDE6D, and UNC119 (depicted in green). (B) Folding: Two responses that are activated upon protein
misfolding are the unfolded protein response (UPR) and the heat shock response (HSR). Both responses
result in enhanced expression of chaperones (depicted in green) in order to restore the correct folding
of proteins. (C) Degradation: ER-associated degradation (ERAD) results in the degradation of proteins
by the ubiquitin–proteasome system (UPS). Another pathway of protein degradation is autophagy.
Background colors in figure (green, blue, and red) correspond with ackground colors of Table 1.
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Table 1. Therapeutic compounds directed against the different branches of the proteostasis network (PN). Therapeutic compounds are divided based on which branch
of the PN they target, including trafficking (green), folding (blue), and degradation (red). Subgroups include compounds directed against protein lipid-modifications,
(co-)chaperonins, HSR, UPR, ERAD, and autophagy. * Compounds that are not yet available.
Target Compounds * Function Effect on PRs References
Protein lipid-modifications FTase inhibitors Inhibits the farnesylation of proteins (Proposed) underprenylation and mislocalization of many PRproteins [100,101]
GGTase-I inhibitors Inhibits the geranylgeranylation of proteins (Proposed) underprenylation and mislocalization of many PRproteins [102]
(Co-)chaperonins CCT inducers * Improves folding of transducin and possibly otherPR proteins Undetermined [103]
PhLP1 inducers * Improves function of CCTs and possiblyCCT-independent functions
Malformation of OS by transgenic expression of a PhLP1
dominant-negative mutant [47,103,104]
CCT-BBSome stabilizers * Stabilizes BBSome formation and thereby theexport of molecules from the OS Undetermined [105]
Small molecule Ric8 inhibitors * Prevents folding of disease-causing Gα Undetermined [106,107]
Heat shock response (HSR) geldanamycin, tanespimycin,alvespimycin 1st generation HSP90 inhibitors
Geldanamycin not suitable for future experiments because of poor
applicability and toxicity; Tanespimycin reduced mutant protein
accumulation in rat RP model (R135L); prolonged treatment with
alvespimycin leads to PR cell death
[108–112]
luminespib, onalespib,
ganetespib, HSP990 Newer generation HSP90 inhibitors
HSP990 treatment in a RP rat model (P23H) enhances visual
function and delayed PR degeneration, but prolonged treatment
led to visual impairment by GRK1 and PDE6 reduction; prolonged
treatment with ganetespib led to PR cell death
[109,111,112]
AAV-HSF-1 Overexpressing HSF-1 and thereby transcriptionalactivation of HSPs
Subretinal injection of AAV-Hsf-1 in a RP rat model (P23H)
improved visual reponse [113]
Arimoclomol Induces HSR and UPR, only in stressed cells Prolonged PR survival and improved visual responses in P23Htransgenic rats [114]
Unfolded protein response
(UPR) AAV-BiP
Relieves ER stress by reducing cleaved ATF6,
phosphorylated eIF2α and CHOP
Subretinal delivery of AAV5-BiP reduced PR cell death and
improved visual responses in P23H transgenic rats [115,116]
CHOP inhibitors * Inhibits proapoptotic transcription activity ofCHOP
CHOP knockout in a trangenic mouse model of RP (T17M) led to
PR cell death and strong impairment in visual function; CHOP
knockout in P23H RHO mice had no effect on PR survival in young
mice, but partly protected PR degeneration in older mice
[117–119]
ATF4 inhibitors * Inhibits downstream transcription activation ofChop, Ero1, and Gadd34
ATF4 knockdown in T17M RHO mice decreased retinal
degeneration and improved PR survival [120]
GSK2606414A Specific PERK inhibitor Treatment with GSK2606414A in P23H RHO rats accelerated PRcell death and further impaired visual function [121]
Salubrinal Inhibitor of eIF2α dephosphorylation Treatment with salubrinal in P23H RHO rats improved PR survival [121]
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Table 1. Cont.
Target Compounds * Function Effect on PRs References
KIRA6 Allosterically inhibits IRE1α RNase activity Intravitreal injection of KIRA6 in P23H RHO rats increased PRsurvival [122]
Reactive electrophilic species
(RES) modulators * Modulate the effects of RES on IRE1 Undetermined [123–128]
Ceapins Selective inhibitors of ATF6α Undetermined [129,130]
ER-associated degradation
(ERAD)
Kyoto University Substances
(KUSs)
Inhibits VCP’s ATPase activity, without affecting
the cellular functions of VCP
Individual treatment with KUS121 and KUS187 in a rd10 mouse
model preserved ONL thickness and improved visual function [131]
AAA+ protein derivatives * Unfolding of misfolded proteins Transgenic expression of PAN in Gy-/- mice increased PR survivaland preserved visual function [132]
DUB/USP modulators Modulating the ubiquitin cleavage from proteins,thereby modulating proteosomal degradation Undetermined [133–135]
Autophagy Rapamycin, everolimus,temsirolimus, ridaforolimus
Inhibiting mTOR pathway by directly binding to
mTORC1 Improved rod survival in P23H-3 rats [136]
Metformin Activation of AMP-activated protein kinase(AMPK)
Metformin treatment protected against retinal cell death in diabetic
mice, whereas it accelerated PR degeneration in P23H RHO mice [137,138]
Valproic acid (VPA) Upregulates autophagy by inhibiting inositolsynthesis
VPA treatment in BBS12-/- mice, P23H RHO Xenopus laevis, and a
rd1 mouse model resulted in PR protection, whereas treatment in
T17M RHO X. laevis, a P23H-1 rat model, and a rd10 mouse model
excerbated PR degeneration
[139–141]
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3. Therapeutic Approaches to Restore Protein Balance
The light sensing OS of PRs requires renewal every ten days due to its high photoactivity, especially
of the cones during daytime vision. This demands a high turnover of biosynthetic compounds, including
membranes and proteins). Therefore, a well-balanced proteostasis network is of particular importance
for the PRs. For many IRDs it has been shown that this balance in the PRs is disrupted, leading to
protein accumulation in the IS and eventually the death of photoreceptors. For this reason, several
studies have focused on therapeutically targeting the three main branches of the PR proteostasis
network to restore the protein balance. The different therapeutic approaches and their effects on PRs
are discussed below and summarized in Table 1.
3.1. Therapeutic Strategies Involved in Protein Trafficking
3.1.1. Targeting Protein Lipid Modifications
Agents targeting prenylation have been extensively studied in cancer research. The first agents
tested were FTase inhibitors used to target the farnesylation of K-Ras, which was shown to induce
several forms of cancer, including colorectal cancer and lung cancer [142]. Although some clinical
improvements were seen for different forms of cancer, these improvements could not be related to
inhibition of K-Ras. Subsequent experiments revealed that K-Ras was geranylgeranylated when
farnesylation was blocked by FTase inhibitors [143]. Therefore, inhibitors of GGTase-I emerged as
potential target for cancer therapy. However, a phase I clinical trial investigating a dual FTase and
GGTase-I inhibitor showed dose-limiting side effects in patients with locally advanced pancreatic
cancer, indicating that inhibition of prenylation has a broad detrimental effect on human health [102].
FTase inhibitors are also of particular interest in the Hutchinson–Gilford progeria syndrome (HGPS)
research field. HGPS is a rare premature-aging disease caused by a dominant de novo point
mutation in the LMNA gene, resulting in the expression of a mutant form of lamin A, also known
as progerin [144]. Progerin remains persistently farnesylated, which makes it a suitable candidate
for FTase inhibitors [100]. Although, promising improvements in bone structure, vascular stiffness,
and hearing have been obtained using FTase inhibitors in HGPS patients, nothing is reported about
possible dose-limiting side effects [101].
Despite the promising results of using FTase and GGTase-I inhibitors for targeting several forms
of cancer and HGPS, the side effects are of major concern; especially in the highly compartmentalized
PRs, where many proteins depend on prenylation for subcellular trafficking and anchoring. General
inhibition of prenylation would probably lead to underprenylation of many PR proteins leading to
mislocalization and accumulation of these proteins in the IS. Therefore, inhibition of prenylation in
PRs will rather accelerate protein accumulation than decreasing it.
3.2. Therapeutic Strategies Involved in Protein Folding
3.2.1. Targeting Chaperonins and Their Co-chaperones
The type II chaperonin CCT is proposed to be involved in the folding of approximately 10% of
newly translated cytosolic proteins [145]. Besides ATP, CCT also needs the co-chaperone PhLP1 for
the correct folding of these proteins [47]. It has been shown that inhibition of CCT by the transgenic
expression of a dominant-negative mutant of PhLP1 results in the malformation of the OS in mouse
photoreceptors [103]. Proteomic analysis revealed that the expression of several important PR proteins
was affected, including PDE6, rhodopsin, transducin, peripherin 2, ROM1, musashi-1, and UNC-119.
It could be possible that CCT is responsible for the folding of these proteins. Yet, only transducin has
been shown to be a direct substrate of CCT. Therefore, a more plausible explanation would be that
PhLP1 regulates the expression of these proteins in a CCT-independent manner.
Besides transducin, the BBSome is also a substrate for CCT for its correct folding and assembly.
It has been shown that some of the BBSome proteins, including BBS6, BBS10, and BBS12, can form a
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CCT-like complex together with CCT subunits. Interestingly, 50% of clinically diagnosed BBS cases are
caused by a mutation in one of these three genes. Furthermore, mutations in these genes result in a
more severe phenotype compared to other BBS proteins [105].
These findings highlight the importance of chaperone defects as pathogenic factors and therefore
as potential therapeutic targets. Surprisingly, chaperonins and their co-chaperones, such as PhLP1,
have not been investigated in relation to therapy. Especially PhLP1 would be an interesting therapeutic
target, because of its proposed CCT-dependent and CCT-independent regulation of important PR
proteins [104].
In cancer research, RIC8, functioning as GEF and chaperone for Gα, has been proposed as a
potential therapeutic target, since it has been shown that constitutive activation of Gα by somatic
mutations leads to development of various cancers [106]. Therefore, inhibition of RIC8 by small
molecules might reduce tumorigenesis. A constitutive active mutant of rod Gα has also been associated
to a form of congenital stationary night blindness [107]. RIC8 inhibition might therefore also alleviate
or delay this phenotype. However, as described earlier, the function of RIC8 in the PR has not been
investigated and inhibition of RIC8 would only be applicable to this specific mutation.
3.2.2. Targeting the Heat Shock Response (HSR)
HSP90, a component involved in the HSR, is commonly overexpressed in multiple forms of
cancer [146]. It has been proposed that cancer cells increase their HSP90 expression and thereby
change their proteostasis network in order to adapt to dysregulated and misfolded protein synthesis
as a consequence of rapid cell division [147]. For this reason, many studies have focused on
investigating HSP90 inhibitors. The first HSP90 inhibitor identified was geldanamycin, but this never
reached the clinical testing phase because of its poor applicability and toxicity [108]. Nevertheless,
geldanamycin paved the way for production of geldanamycin analogs, including 17-AAG/tanespimycin
and 17-DMAG/alvespimycin [109]. Although clinical testing was halted for these agents, it did provide
proof-of-principle that HSP90 is a relevant target for cancer therapy. Now, a new generation of
HSP90 inhibitors, including luminespib, onalespib, and ganetespib, show greater potency in clinical
testing [109].
HSP90 inhibitors have also been tested in models for retinal degeneration. Systemic administration
of 17-AAG accompanied by inner-blood retina barrier modulation in a mouse model of RP (RP10)
protects against photoreceptor degeneration induced by aggregating RP10-associated mutant IMPDH1
protein [110]. Furthermore, HSP90 inhibition by 17-AAG in a transgenic rat model of RP (R135L)
reduced the intracellular accumulation of the mutant protein and restored the localization of this
protein comparable to wild type controls [111]. Administration of another HSP90 inhibitor, HSP990,
in a different transgenic rat model of RP (P23H) resulted in enhanced visual function and delayed
photoreceptor degeneration. However, prolonged treatment with HSP990 leads to a reduction in
GRK1 and PDE6 protein levels followed by visual impairment [111]. The visual impairment caused
by prolonged HSP90 inhibition is in line with findings from a study in which four HSP90 inhibitors
were tested, including 17-AAG, 17-DMAG, luminespib, and ganetespib, in a rat retinal damage model.
Here, it was shown that prolonged inhibition with 17-DMAG and ganetespib results in PR cell death,
whereas there was no PR injury detected upon treatment with the other two agents [112].
These contradictory findings might be explained by the different modes of action of the HSP90
inhibitors, since the effect of 17-AAG was dependent on HSF1 in the P23H rat model, whereas its effect
was HSF1-independent in the R135L model. This is further supported by the notion that HSP90 is
known to facilitate the folding and assembly of more than 300 proteins [146]. Alternatively, agents that
induce the HSR in other ways might be more suitable as potential treatments for IRDs. A direct way to
target the HSR is by overexpressing the HSF-1 gene. A study in the p23H RHO RD rat model showed
a significant increase of scotopic electroretinogram (ERG) amplitudes compared to untreated controls
upon ectopic overexpression of HSF-1 by subretinal injection of AAV-HSF-1 [113].
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The hydroxylamine derivative arimoclomol might be a more indirect alternative agent to induce
the HSR. Treatment of transgenic rats, carrying a P23H rhodopsin mutation, with arimoclomol resulted
in improved PR OS structure and reduced rhodopsin accumulation in the IS, accompanied by prolonged
PR survival and improved visual responses [114]. It was shown that these improvements were mediated
by both the HSR and the UPR, thereby indicating that these responses are intertwined. Another great
advantage of arimoclomol is that it only acts on stressed cells. In this way, potential side effects, as a
consequence of inducing an HSR response in healthy cells present in the retina, are avoided.
3.2.3. Targeting the Unfolded Protein Response (UPR)
As described earlier, the UPR senses ER stress by using three transmembrane sensors, including
IRE1, PERK, and ATF6. In IRDs, mutations causing defective proteins can result in prolonged ER stress.
It has been shown that upon prolonged ER stress, downstream effectors of the PERK pathway, ATF4 and
CHOP heterodimerize. This results in increased protein synthesis, protein misfolding, and oxidative
stress, eventually leading to cell death [148]. Another branch of the UPR that gets hyperactivated upon
prolonged ER stress is IRE1. Hyperactive IRE1 cleaves microRNAs that normally inhibit proapoptotic
targets, thereby inducing apoptosis [149]. Because apoptosis as a consequence of ER stress is often
seen in PRs of IRD patients, therapeutically targeting UPR regulators or pathways involved in one of
the three branches of the UPR might promote PR survival and thereby visual function.
As discussed earlier, it is commonly accepted that BiP/GRP78 is the key regulator in the activation
of the UPR. Therefore, BiP might be a potential therapeutic target for relieving ER stress. Indeed,
studies have shown that subretinal delivery of AAV5-BiP to a transgenic rat model of RP (P23H) results
in reduction of PR cell death and improved ERG amplitudes [115]. Furthermore, a study in primary
human retinal pigmented epithelium cells (hRPE) showed that AAV2-BiP promotes the survival of
these cells under ER stress [116]. Both studies suggest that these improvements are due to a suppression
of apoptosis by downregulation of CHOP protein levels. For this reason, reducing CHOP levels might
be a promising strategy to alleviate ER stress. This notion is supported by a large body of evidence in
the field of Alzheimer’s Disease, cardiac hypertrophy, and diabetes, wherein they link CHOP to these
disease conditions [150].
Recently, several studies investigated the effect of CHOP reduction in the context of photoreceptor
degeneration. A first study was performed in a transgenic mouse model of RP (T17M) [117].
Subsequently, these mice were crossed with CHOP knockout mice in order to get T17M RHO
CHOPP−/− mice. Complete knockdown of CHOP in these mice resulted in photoreceptor cell death,
indicated by significant thinning of the outer nuclear layer, accompanied by a strong impairment in
visual function. In a similar experimental setup comparing P23H RHO CHOPP−/− mice with P23H
RHO mice, they found no effect on PR survival in young animals. In older mice, however, the central
retina of the CHOPP−/− mice was partly protected against degeneration [118]. Another study in
transgenic mice expressing human P23H rhodopsin also showed that knockout of CHOP had no effect
on the rescue of retinal degeneration [119]. These studies indicated that complete ablation of CHOP
has no positive effect in early developmental stages. As already described earlier, CHOP is mainly
involved in prolonged PERK activation. Therefore, reducing CHOP levels to physiological levels
during prolonged ER stress might be a better solution. This notion is supported by above described
findings in older mice.
Interestingly, knocking down the proapoptotic partner of CHOP, ATF4 in a T17M rhodopsin
mutant mouse model resulted in decreased retinal degeneration and improved PR survival [120].
Further support that the PERK branch of the UPR might be a promising therapeutic target comes
from studies investigating ER stress related diseases, including Alzheimer’s Disease (AD), amyotrophic
lateral disease (ALS), Parkinson’s Disease, and prion diseases [151,152].
In an Alzheimer’s disease mouse model it was shown that deletion of PERK resulted in decreased
phosphorylation of eIF2α and prevented deficits in protein synthesis leading to an improvement of
the AD phenotype in these mice [153]. Comparable results were obtained in prion-diseased mice by
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overexpressing GADD34, which plays a role in the negative feedback loop for PERK by acting as a
cofactor in the dephosphorylation of eIF2α [154]. Treatment of the prion-diseased mice with salubrinal,
an inhibitor of eIF2α dephosphorylation, had the opposite effect compared to GADD34 overexpression,
thereby supporting the positive effects of eIF2α dephosphorylation. The positive effect of the inhibition
of the PERK pathway is further supported by a study investigating the effect of the specific PERK
inhibitor, GSK2606414A, in prion-diseased mice [155]. Treatment with this inhibitor showed reduced
neuronal cell death leading to increased survival of these mice.
Surprisingly, opposing results were found for GSK2606414A and salubrinal treatment when
administered in P23H RHO transgenic rats. GSK2606414A treatment resulted in accelerated
photoreceptor cell death and further impaired visual function, whereas salubrinal treatment was found
to improve photoreceptor survival [121]. It could be possible that in some disease conditions or models
the PERK pathway is protective, whereas in other conditions it is rather a secondary effect of the
disease process. Therefore, targeting other branches of the UPR might overcome this issue.
Targeting the IRE1 branch of the UPR has been shown to be beneficial in multiple rodent
models, including a P23H RHO rat model [122]. In this model, intravitreal injection of KIRA6, which
allosterically inhibits the RNase domain of IRE1, showed increased photoreceptor survival.
Recently, an emerging role of reactive electrophilic species (RES) as key regulators for the UPR,
more specifically the IRE1 pathway, have been described [123]. Furthermore, RES have been reported
to be involved in ER-stress related diseases, including neurodegenerative diseases, amyotrophic lateral
sclerosis (ALS), and cancer [124–126]. The RES nitric oxide (NO) has been shown to modulate PDI and
IRE1 through S-nitrosylation and thereby inhibiting the IRE1 branch of the UPR [127,128]. Therefore,
modulation by RES might be a new potential therapeutic strategy for ER stress-associated diseases,
including IRDs.
Maybe the most interesting sensor of the UPR, in context of IRDs, is ATF6, because mutations in
ATF6 have been shown to cause autosomal recessive achromatopsia and early onset photoreceptor
degeneration, also affecting the macula [156,157].
Until recently, no compounds were available that specifically target the ATF6 branch of the UPR.
However, by cell-based screens a new class of pyrazole amides, named Ceapins, were identified as
selective inhibitors of ATF6α [129,130]. Ceapins selectively prevent transport of AFT6α to the Golgi
apparatus during ER stress. Interestingly, Ceapins have no toxic impact on unstressed cells, whereas
they increase ER stress sensitivity upon ER stress induction.
3.3. Therapeutic Strategies Involved in Protein Degradation
3.3.1. Targeting the ER-associated Degradation (ERAD)
One of the essential players in ERAD is p97/VCP, belonging to the type II AAA+ protein family of
ATPases. Because of its essential role in ERAD, VCP is proposed as a novel therapeutic target for the
treatment of various diseases, including cystic fibrosis, cancer, and neurodegenerative disorders [131].
Besides its function in retrotranslocation and protein degradation, VCP is also involved in many other
cellular processes, including mitosis, nuclear reformation, DNA/RNA repair, aggresome formation
and inflammatory signaling [158]. Therefore, for therapeutic applicability, selective intervention of
VCP is required to minimize the side effects. Small compounds, named Kyoto University Substances
(KUSs), might fulfill these criteria. KUSs have been shown to specifically inhibit VCP’s ATPase activity,
without affecting the cellular functions of VCP [131]. Administering KUSs, more specifically KUS121
or KUS187, by intraperitoneal injection in a rd10 mouse model resulted in preserved outer nuclear
layer (ONL) thickness and improved visual function measured by ERG.
Because of the unfolding properties of VCP also other AAA+ proteins have been proposed as potent
therapeutic agents, especially in solving protein misfolding and aggregation in neurodegenerative
diseases. Although not functionally related to ERAD, the repurposing of two AAA+ proteins, including
Hsp104 and proteasome-activating nucleotidase (PAN) were shown to protect from protein misfolding
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in several neurodegenerative animal models [159]. Furthermore, transgenic expression of PAN in
rods of mice lacking the γ-subunit of transducin (Gγ−/−) resulted in increased photoreceptor survival
accompanied by preserved visual function [132].
Another possible therapeutic target of ERAD could be the enhancement of proteosomal
degradation. Important players in this process are the deubiquitination enzymes (DUBs), also
known as ubiquitin-specific proteases (USPs). USPs are known to cleave ubiquitin moieties from
proteins and thereby preventing these proteins from proteosomal degradation [133]. Therefore,
inhibiting USPs might work as a therapeutic approach to stimulate the degradation of misfolded
proteins by the proteasome. In cancer research inhibition of specific USPs, including USP7 and USP10,
has already been shown to have beneficial effects, by acting on the tumor suppressor p53 [134].
Depending on the type of mutation, p53 can either gain oncogenic properties or lose its tumor
suppressor ability [160]. Therefore, based on the mutant form of p53, either increasing or lowering the
levels of p53 could be beneficial. Inhibiting USP7, a negative regulator of p53, leads to increased p53
levels, whereas inhibiting USP10, a positive regulator of p53, leads to reduction of p53 levels [134].
With this in mind, the causative mutation for the disease has to be known, as well as the specificity of
the USP inhibitor before administering it to the patient. From discrepancies in findings of different
studies it cannot be concluded whether p53 is involved in the pathogenesis of PR cell death [161,162].
However, a recent study found a biallelic mutation in USP45 associated with LCA. This indicates that
USPs can play important roles in the pathogenesis of PR degeneration [163].
Another important issue to address is that DUBs associated with VCP have been suggested to
promote protein turnover by assisting in retrotranslocation instead of their traditional function in
preventing proteasomal degradation. Therefore, inducing these specific VCP associated DUBs might
have therapeutic potential [135].
3.3.2. Targeting Autophagy
One of the best known inducers of autophagy is rapamycin, which directly binds to mTORC1,
thereby inhibiting the mTOR pathway [164]. Because of its limited absorption, studies have been
focusing on investigating rapamycin analogs or rapalogs, including everolimus, temsirolimus, and
ridaforolimus. These mTORC1 inhibitors were highlighted as promising therapeutic agents in various
protein misfolding associated diseases, including neurodegenerative diseases and multiple forms of
cancer [165,166]. Also, a study in an RP rat model has shown the therapeutic potential of rapamycin in
treating blindness [136]. In this study, rod cell degeneration was slowed down, without affecting cones,
in a P23H rat model upon systemic administration of rapamycin. In contrast, other studies showed
that activation of the mTOR pathway promotes cone survival [167–169]. Taken together, these results
indicate that activation of autophagy is particularly protective for rods, but can have opposing effects
on cones.
Studies investigating other mTOR inhibitors, including ATP-competitive mTOR inhibitors, are
emerging [170]. Furthermore, indirect modulators of the mTOR pathway, including metformin and
nilotinib have also been shown to play a protective role in diabetes, cancer, and neurodegenerative
diseases via indirect activation of AMPK [171–173]. Contradictory results are found in mouse models
of retinal degeneration when treated with metformin. In diabetic mice, metformin treatment protected
against retinal cell death, whereas in a P23H RHO mouse model it accelerated the photoreceptor
degeneration, indicating different modes of action by metformin [137,138].
In addition to autophagy upregulators acting on the mTOR pathway, also mTOR-independent
autophagy upregulators have been widely studied, mainly in Huntington’s disease [174]. One such
agent is valproic acid (VPA), which upregulates autophagy by inhibiting inositol synthesis. In line
with findings in neurodegeneration models, VPA treatment in models for photoreceptor degeneration
can be detrimental or protective [139,175]. In a mouse model for Bardet–Biedl syndrome (BBS12−/−),
as well as in a Xenopus laevis model for RP (P23H) treatment with VPA resulted in photoreceptor
protection [139,140]. In contrast, a T17M X. laevis model of RP and the P23H-1 rat model showed
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exacerbated photoreceptor degeneration upon VPA treatment [15,139]. Even in mouse models with a
different mutation in the same gene (PDE6) this discrepancy in outcome was observed: VPA treatment
reduced photoreceptor loss in the rd1 model, whereas VPA treatment slightly accelerated photoreceptor
loss in the rd10 model [141]. Taken together, these studies indicate that the outcome of VPA treatment
depends on the genotype and even on the type of mutation. The conflicting results might be partly
explained by the different modes of action by VPA, since VPA is also acting as a histone deacetylase
(HDAC) inhibitor, thereby altering expression of different genes [176].
4. Discussion and Outlook
The OS of the PR can be considered as a highly specialized cilium responsible for the conversion of
light stimuli into electrical signals, also known as the phototransduction cascade. This cascade requires
a tremendous amount of energy as well as a continuous OS protein turnover to maintain cellular
homeostasis. Therefore, a perfectly balanced proteostasis network is of particular importance for the
PRs. In many IRDs this balance is disrupted leading to protein accumulation in the IS and ultimately
to PR cell death. Several attempts were made to restore this balance by therapeutically targeting
different branches of the proteostasis network, including protein trafficking, folding, and degradation.
For therapeutic intervention, it has to be taken into account that these different branches consist of
tightly intertwined processes, which depend on each other and influence each other’s function and
activation. For example, administration of the AMPK activator metformin to P23H RHO mice resulted
in enhanced trafficking of rhodopsin to the rod OSs. However, it still led to reduced PR function and
survival. Apparently, metformin did not succeed in full restoration of the correct folding of rhodopsin,
leading to increased destabilization of the OSs [137]. Taken together, enhancing protein trafficking
without improving protein folding will accelerate the disease progression rather than diminishing it.
Recently, also an intimate cross-talk between the UPR, more specifically IRE1, and ERAD has been
described [177]. On one hand, splicing of XBP1s by activated IRE1 promotes the expression of ERAD
components, while on the other hand ERAD serves as a feedback loop for IRE1 by targeting it for
degradation. This cross-talk is probably further extended to other branches of the UPR, since it has
been shown that the turnover of ATF6 is also regulated by ERAD [178].
Another issue that has to be taken into account for therapeutic intervention is that in some
disease conditions certain branches of the proteostasis network are protective, whereas in other disease
conditions it is a consequence of the disease process. Therefore, it is often not clear which branch of the
proteostasis network would be the most effective target to treat a certain disease type. Even different
mutations in the same gene causing similar disease conditions can have an effect on the treatment
outcome, indicated by contradictory findings in VPA treatment in the rd1 and rd10 mouse models [141].
This discrepancy might be partly explained by the severity of the gene mutations leading to different
rates of disease progression, since rd1 mice show rapid degeneration of PRs, whereas the rd10 mouse
model represents a more slowly progressive form of RP. With this in mind, therapeutic compounds
that have an positive effect on slow progressing forms of RP might not be suitable for fast progressing
forms of RP and early onset forms of blindness, such as LCA.
The animal model used for therapeutic testing, especially animals carrying a transgene, can
also influence therapeutic outcome. One such animal model carrying a transgene is the P23H RHO
rat model. Numerous different lines with various transgene expression exist [179–181]. It has been
shown that the amount of expression of the transgene can have an effect on the disease phenotype.
Even overexpression of wild type human rod opsin has been shown to induce PR degeneration [182].
In contrast, it has been shown that overexpression of wild type RHO partially rescues visual responses
in a P23H RHO rat model [113]. Nevertheless, studies using the P23H RHO rat model presented in
this review should be interpreted with caution, especially when translating therapeutic outcome to the
patient situation.
Instead of directly targeting the different branches of the proteostasis network, mimicking the
actions of these branches might also be a valuable therapeutic approach. The main action of the PERK
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pathway of the UPR is reducing the protein synthesis and thereby reducing the ER-stress load. This
action can also be regulated by targeting the epigenome, including histone acetylation. Enzymes that
play an important role in this acetylation process are the histone deacetylases (HDACs). Inhibiting
these HDACs was shown to be protective for PR cell death. Administration of the HDAC6 inhibitor
tubastatin A in an inherited blindness zebrafish model resulted in the rescue of retinal morphology
and visual function [183]. However, further investigation of the underlying molecular mechanisms is
necessary, since poor efficacy and safety have been reported for other HDAC inhibitors, including
VPA [176,184].
Another way to influence protein synthesis is by the regulation of splicing. The importance
of splicing in the retina is indicated by mutations found in the ubiquitously expressed pre-mRNA
processing factors (PRPFs), which only cause retinal-specific degeneration [185]. In situ gene editing of
a pathogenic, dominant mutation in PRPF31 resulted in the rescue of protein expression as well as
the phenotype [186]. The proof-of-principle for targeting splicing as potential therapeutic strategy is
further supported by the application of antisense oligonucleotides for the treatment of inherited retinal
diseases, including CEP290 associated LCA [20,187].
In addition to influencing protein synthesis, degeneration of PRs, which is the ultimate consequence
of sustained ER-stress and a key hallmark of IRDs, can also been seen as a therapeutic target. A broad
range of therapeutic agents is available that can be protective for PR cell death, including cell
death inhibitors, caspase modulators, and neurotrophic factors. Individual treatment of P23H-1 rats
with the known cell death inhibitors calpeptin, N-acetylcysteine, and necrostatin-1s all resulted in
improved photoreceptor function [188]. Furthermore, the chemical chaperone tauroursodeoxycholic
acid (TUDCA), which inhibits apoptosis by preventing BAX from being transported to the mitochondria
to initiate caspase release, has been shown to preserve cones in a LCA mouse model upon systemic
injection [189]. On top of that, direct inhibition of caspases by subretinal AAV delivered X-linked
inhibitor of apoptosis (XIAP) in two RP rat models protected PR structure and function [190]. Finally,
neurotrophic factors, including CNTF, BDNF, GDNF, LEDGF, PEDF, and RdCVF were also found to
have positive effects on PR survival [191]. However, the therapeutic potential of neurotrophic factors as
a general treatment may not outweigh the plausible risk of side effects. These side effects can be reduced
by carefully selecting the proper administration route, which accounts for every therapeutic agent
described in this review. In general, there are three possible delivery methods to reach the eye: systemic,
topical, and local. Each of these methods have their advantages and disadvantages [192]. Systemic
delivery is often accompanied by systemic side effects and drugs need to pass the blood–retinal barrier
first to perform their function, but it is less invasive compared to intraocular injections. Topical delivery
in form of eye drops or ointments is not invasive, but the chance that the therapeutic compound
reaches its destination is often an issue. Intraocular injection is the most invasive delivery method,
but most often also the most effective one. Furthermore, with this method the involvement of the
immune system is largely circumvented, as the eye is a largely immune-privileged organ, thereby
further reducing the risk of potential side effects. Intraocular delivery can be performed by injecting
the therapeutic compound by itself, but the cell penetrance and thus delivery efficiency is much higher
when the compound is packed into nanoparticles, for example [192].
Immense progress has been made in optimizing the delivery methods in combination with the drug
formulation, especially for gene augmentation and antisense-oligo nucleotide (AON)-based treatments.
Now, an increasing number of studies are aimed at developing broader applicable treatments, and
therefore are focused on therapies targetting the proteostatis network. Many of these studies show
hopeful results in delaying blinding conditions [111,114,121,122,131]. However, much effort has still to
be made to first efficiently halt the progression of IRD, let alone fully restore vision.
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